Table 3.
Associations of categories of TNFR1 and TNFR2 change with ESKD in AASK
| Biomarker category | # events/# at risk | Unadjusted | Adjusteda | ||
|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | ||
| TNFR1 | |||||
| Persistently low (low–low) | 29/275 | Ref | Ref | Ref | Ref |
| Decreasing (high–low)b | 7/14 | 5.74 | 2.51 to 13.14 | 3.48 | 1.46 to 8.30 |
| Increasing (low–high) | 26/39 | 13.06 | 7.62 to 22.39 | 6.47 | 3.58 to 11.67 |
| Persistently elevated (high–high) | 67/90 | 17.39 | 11.08 to 27.29 | 7.34 | 4.03 to 13.38 |
| TNFR2 | |||||
| Persistently low (low–low) | 37/272 | Ref | Ref | Ref | Ref |
| Decreasing (high–low)b | 7/21 | 2.69 | 1.20 to 6.05 | 1.67 | 0.74 to 3.77 |
| Increasing (low–high) | 28/42 | 10.54 | 6.38 to 17.41 | 5.31 | 3.11 to 9.06 |
| Persistently elevated (high–high) | 57/83 | 10.94 | 7.16 to 16.72 | 3.85 | 2.29 to 6.45 |
Ref, reference.
Adjusted for age, sex, systolic BP, body mass index, smoking, glomerular filtration rate, and ln(UPCR) at 0 months. Categories defined by whether biomarker levels at 0 and 24 (or 12 if not available) months were > or ≤ the 75th percentile for the biomarker level at 0 months (persistently low: ≤ at both 0 and 24 (or 12 if not available) months; decreasing: > at 0 months and ≤ at 24 (or 12 if not available) months; increasing: ≤ at 0 months and > at 24 (or 12 if not available) months; persistently elevated: > at both 0 and 24 (or 12 if not available) months.
In the adjusted model, when the decreasing category was used as the reference, the increasing and persistently elevated categories were worse for TNFR2 (adjusted HR 3.19 [95% CI, 1.35 to 7.50] and adjusted HR 2.31 [95% CI, 1.00 to 5.34], respectively) but not TNFR1.